A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Chronic Spontaneous Urticaria
Related studies linked through entity extraction aliases.
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)
- Status
- COMPLETED
- Phase
- PHASE3
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.
- Status
- COMPLETED
- Phase
- PHASE1
A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria
- Status
- UNKNOWN
- Phase
- PHASE2
Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria
- Status
- AVAILABLE
- Phase
- N/A
STOP CSUA: phySical acTivity, mOod and sleeP in Chronic Spontaneous Urticaria and Angioedema
- Status
- UNKNOWN
- Phase
- N/A
A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria
- Status
- WITHDRAWN
- Phase
- PHASE2
Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine
- Status
- COMPLETED
- Phase
- PHASE2
A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines
- Status
- COMPLETED
- Phase
- PHASE3
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines
- Status
- COMPLETED
- Phase
- PHASE3
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines
- Status
- COMPLETED
- Phase
- PHASE3
Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria
- Status
- UNKNOWN
- Phase
- PHASE3
Global Managed Access Program Cohort for Ligelizumab in CSU
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Efficacy of Low-dose Interleukin-2 Treatment in Chronic Spontaneous Urticaria
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria
- Status
- COMPLETED
- Phase
- PHASE2